Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705292 | 0.84 | TSHR (0.35) | — | |
| SCHEMBL17705297 | 0.82 | PDE2A (0.33) | HDAC1HDAC6 | |
| SCHEMBL17705291 | 0.81 | HDAC1 (0.32) | HDAC1HDAC6 | |
| SCHEMBL19258266 | 0.77 | RAPGEF4 (0.32) | — | |
| SCHEMBL18750573 | 0.73 | CA1 (0.33) | — | |
| SCHEMBL12829125 | 0.73 | GPR3 (0.36) | MAPT | |
| SCHEMBL17147820 | 0.73 | CYP3A4 (0.43) | — | |
| SCHEMBL17705295 | 0.72 | KIF11 (0.37) | — | |
| SCHEMBL1859691 | 0.72 | PDE2A (0.50) | NOTUMTP53MAPT | |
| SCHEMBL10052628 | 0.72 | ACHE (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822305-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-9809749-B2 | Mesogenic compound, liquid-crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9593279-B2 | Liquid-crystalline medium and high-frequency components comprising same | MERCK PATENT GMBH (DE) | 2017-03-14 | — | — | US | disclosed |
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | BMP2, IK, EML4 | HDAC1 3111/4885HDAC6 3547/4885NOTUM 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.